Reports Q4 revenue $8.45M, may not compare to consensus $6.06M. “At December 31, 2018, we had $337.8 million in cash and cash equivalents. We expect our current cash to fund our operations through data readouts for our three ongoing registrational clinical trials.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.